Details for Patent: 11,793,766

« Back to Dashboard

Which drugs does patent 11,793,766 protect, and when does it expire?

Patent 11,793,766 protects ZTLIDO and is included in one NDA.

This patent has twenty-four patent family members in nineteen countries.

Summary for Patent: 11,793,766

Title:	Non-aqueous patch for the relief of pain
Abstract:	[Problem] If lidocaine is composed of non-aqueous patch, the adhesive power of the preparation tends to get lower, as the composition amount of lidocaine is higher. It is popular to solve lidocaine in dissolving agent in order to compose lidocaine in patch and release effective amount into skin. However, if the amount of dissolving agent gets higher, the adhesive power gets extremely lower, so that an long-time attachment is difficult.[Solution]A non-aqueous patch comprising lidocaine and/or its reactant, and a dissolving agent which are contained in a base of plaster, the plaster being hold by a support, of which strength of 50% stretched to longitudinal direction is less than 2000 g/50 mm and of biaxially-oriented stretch cloth.
Inventor(s):	Tatsuya Mori, Naoyuki Saida
Assignee:	Oishi Koseido Co Ltd , Itochu Chemical Frontier Corp
Application Number:	US16/941,413
Patent Claim Types: see list of patent claims	Use;

Drugs Protected by US Patent 11,793,766

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Scilex Pharms	ZTLIDO	lidocaine	PATCH;TOPICAL	207962-001	Feb 28, 2018	AB	RX	Yes	Yes						METHOD FOR RELIEVING THE PAIN ASSOCIATED WITH POST-HERPETIC NEURALGIA

International Family Members for US Patent 11,793,766

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Brazil	112014006719
Canada	2850024
Cyprus	1120754
Denmark	2823815
European Patent Office	2823815
European Patent Office	3363432
Spain	2683006